Cancer Research Targets Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barthel, H.
Right arrow Articles by Aboagye, E. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barthel, H.
Right arrow Articles by Aboagye, E. O.
[Cancer Research 63, 3791-3798, July 1, 2003]
© 2003 American Association for Cancer Research

Tumor Biology

3'-Deoxy-3'-[18F]Fluorothymidine as a New Marker for Monitoring Tumor Response to Antiproliferative Therapy in Vivo with Positron Emission Tomography1

Henryk Barthel, Marcel C. Cleij, David R. Collingridge, O. Clyde Hutchinson, Safiye Osman, Qimin He, Sajinder K. Luthra, Frank Brady, Pat M. Price and Eric O. Aboagye2

Cancer Research United Kingdom PET Oncology Group, Department of Cancer Medicine, Faculty of Medicine, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, London W12 0NN, United Kingdom [H. B., M. C. C., D. R. C., O. C. H., P. M. P., E. O. A.]; Imaging Research Solutions Limited, Cyclotron Building, Hammersmith Hospital, London W12 0NN, United Kingdom [S. O., S. K. L., F. B.]; Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germany [H. B.]; and Department of Oncology, Clinical Research Laboratory, Huddinge University Hospital, Karolinska Institute, S-171 76 Stockholm, Sweden [Q. H.]

3'-Deoxy-3'-[18F]fluorothymidine ([18F]FLT) has been proposed as a new marker for imaging tumor proliferation by positron emission tomography (PET). The uptake of [18F]FLT is regulated by cytosolic S-phase-specific thymidine kinase 1 (TK1). In this article, we have investigated the use of [18F]FLT to monitor the response of tumors to antiproliferative treatment in vivo. C3H/Hej mice bearing the radiation-induced fibrosarcoma 1 tumor were treated with 5-fluorouracil (5-FU; 165 mg/kg i.p.). Changes in tumor volume and biodistribution of [18F]FLT and 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) were measured in three groups of mice (n = 8–12/group): (a) untreated controls; (b) 24 h after 5-FU; and (c) 48 h after 5-FU. In addition, dynamic [18F]FLT-PET imaging was performed on a small animal scanner for 60 min. The metabolism of [18F]FLT in tumor, plasma, liver, and urine was determined chromatographically. Proliferation was determined by staining histological sections for proliferating cell nuclear antigen (PCNA). Tumor levels of TK1 protein and cofactor (ATP) were determined by Western blotting and bioluminescence, respectively. Tumor [18F]FLT uptake decreased after 5-FU treatment (47.8 ± 7.0 and 27.1 ± 3.7% for groups b and c, respectively, compared with group a; P < 0.001). The drug-induced reduction in tumor [18F]FLT uptake was significantly more pronounced than that of [18F]FDG. The PET image data confirmed lower tumor [18F]FLT retention in group c compared with group a, despite a trend toward higher radiotracer delivery for group c. Other than phosphorylation in tumors, [18F]FLT was found to be metabolically stable in vivo. The decrease in tumor [18F]FLT uptake correlated with the PCNA-labeling index (r = 0.71, P = 0.031) and tumor volume changes after 5-FU treatment (r = 0.58, P = 0.001). In this model system, the decrease in [18F]FLT uptake could be explained by changes in catalytic activity but not translation of TK1 protein. Compared with group a, TK1 levels were lower in group b (78.2 ± 5.2%) but higher in group c (141.3 ± 9.1%, P < 0.001). In contrast, a stepwise decrease in ATP levels was observed from group a to b to c (P < 0.001). In conclusion, we have demonstrated the ability to measure tumor response to antiproliferative treatment with [18F]FLT and PET. In our model system, the radiotracer uptake was correlated with PCNA-labeling index. The decrease in [18F]FLT uptake after 5-FU was more pronounced than that of [18F]FDG. [18F]FLT is, therefore, a promising marker for monitoring antiproliferative drug activity in oncology that warrants additional testing.




This article has been cited by other articles:


Home page
 JNMHome page
M. P.S. Dunphy and J. S. Lewis
Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 106S - 121S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. J. Kim, J. S. Lee, K. C. Im, S.-Y. Kim, S.-A. Park, S. J. Lee, S. J. Oh, D. S. Lee, and D. H. Moon
Kinetic Modeling of 3'-Deoxy-3'-18F-Fluorothymidine for Quantitative Cell Proliferation Imaging in Subcutaneous Tumor Models in Mice
J. Nucl. Med., December 1, 2008; 49(12): 2057 - 2066.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H.-J. Sohn, Y.-J. Yang, J.-S. Ryu, S. J. Oh, K. C. Im, D. H. Moon, D. H. Lee, C. Suh, J.-S. Lee, and S.-W. Kim
[18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung
Clin. Cancer Res., November 15, 2008; 14(22): 7423 - 7429.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. K. Buck, M. Bommer, M. E. Juweid, G. Glatting, S. Stilgenbauer, F. M. Mottaghy, M. Schulz, T. Kull, D. Bunjes, P. Moller, et al.
First Demonstration of Leukemia Imaging with the Proliferation Marker 18F-Fluorodeoxythymidine
J. Nucl. Med., November 1, 2008; 49(11): 1756 - 1762.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Leyton, G. Smith, M. Lees, M. Perumal, Q.-d. Nguyen, F. I. Aigbirhio, O. Golovko, Q. He, P. Workman, and E. O. Aboagye
Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901
Mol. Cancer Ther., September 1, 2008; 7(9): 3112 - 3121.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. von Forstner, J.-H. Egberts, O. Ammerpohl, D. Niedzielska, R. Buchert, P. Mikecz, U. Schumacher, K. Peldschus, G. Adam, C. Pilarsky, et al.
Gene Expression Patterns and Tumor Uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an Orthotopic Mouse Xenotransplantation Model of Pancreatic Cancer
J. Nucl. Med., August 1, 2008; 49(8): 1362 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. R. Bading and A. F. Shields
Imaging of Cell Proliferation: Status and Prospects
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 64S - 80S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. K. Buck, K. Herrmann, C. M. z. Buschenfelde, M. E. Juweid, M. Bischoff, G. Glatting, G. Weirich, P. Moller, H.-J. Wester, K. Scheidhauer, et al.
Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine
Clin. Cancer Res., May 15, 2008; 14(10): 2970 - 2977.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. S. Bradbury, D. Hambardzumyan, P. B. Zanzonico, J. Schwartz, S. Cai, E. M. Burnazi, V. Longo, S. M. Larson, and E. C. Holland
Dynamic Small-Animal PET Imaging of Tumor Proliferation with 3'-Deoxy-3'-18F-Fluorothymidine in a Genetically Engineered Mouse Model of High-Grade Gliomas
J. Nucl. Med., March 1, 2008; 49(3): 422 - 429.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. R. Tseng, K. W. Kang, M. Dandekar, S. Yaghoubi, J. H. Lee, J. G. Christensen, S. Muir, P. W. Vincent, N. R. Michaud, and S. S. Gambhir
Preclinical Efficacy of the c-Met Inhibitor CE-355621 in a U87 MG Mouse Xenograft Model Evaluated by 18F-FDG Small-Animal PET
J. Nucl. Med., January 1, 2008; 49(1): 129 - 134.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Herrmann, H. A. Wieder, A. K. Buck, M. Schoffel, B.-J. Krause, F. Fend, T. Schuster, C. Meyer zum Buschenfelde, H.-J. Wester, J. Duyster, et al.
Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma
Clin. Cancer Res., June 15, 2007; 13(12): 3552 - 3558.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H.-M. Wu, G. Sui, C.-C. Lee, M. L. Prins, W. Ladno, H.-D. Lin, A. S. Yu, M. E. Phelps, and S.-C. Huang
In Vivo Quantitation of Glucose Metabolism in Mice Using Small-Animal PET and a Microfluidic Device
J. Nucl. Med., May 1, 2007; 48(5): 837 - 845.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. K. Buck, M. Bommer, S. Stilgenbauer, M. Juweid, G. Glatting, H. Schirrmeister, T. Mattfeldt, D. Tepsic, D. Bunjes, F. M. Mottaghy, et al.
Molecular Imaging of Proliferation in Malignant Lymphoma.
Cancer Res., November 15, 2006; 66(22): 11055 - 11061.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Leyton, M. Lockley, J. L. Aerts, S. K. Baird, E. O. Aboagye, N. R. Lemoine, and I. A. McNeish
Quantifying the Activity of Adenoviral E1A CR2 Deletion Mutants Using Renilla Luciferase Bioluminescence and 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Imaging.
Cancer Res., September 15, 2006; 66(18): 9178 - 9185.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. van Waarde, L. B. Been, K. Ishiwata, R. A. Dierckx, and P. H. Elsinga
Early Response of {sigma}-Receptor Ligands and Metabolic PET Tracers to 3 Forms of Chemotherapy: An In Vitro Study in Glioma Cells
J. Nucl. Med., September 1, 2006; 47(9): 1538 - 1545.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Leyton, J. P. Alao, M. Da Costa, A. V. Stavropoulou, J. R. Latigo, M. Perumal, R. Pillai, Q. He, P. Atadja, E. W.-F. Lam, et al.
In vivo Biological Activity of the Histone Deacetylase Inhibitor LAQ824 Is detectable with 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography.
Cancer Res., August 1, 2006; 66(15): 7621 - 7629.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Apisarnthanarax, M. M. Alauddin, F. Mourtada, H. Ariga, U. Raju, O. Mawlawi, D. Han, W. G. Bornmann, J. A. Ajani, L. Milas, et al.
Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3'-Deoxy-3'-3H-Fluorothymidine Using Preclinical Tumor Models
Clin. Cancer Res., August 1, 2006; 12(15): 4590 - 4597.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. A. Weber
Positron Emission Tomography As an Imaging Biomarker
J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
B. J. Fueger, J. Czernin, I. Hildebrandt, C. Tran, B. S. Halpern, D. Stout, M. E. Phelps, and W. A. Weber
Impact of Animal Handling on the Results of 18F-FDG PET Studies in Mice
J. Nucl. Med., June 1, 2006; 47(6): 999 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. S. Yap, J. Czernin, M. C. Fishbein, R. B. Cameron, C. Schiepers, M. E. Phelps, and W. A. Weber
Evaluation of Thoracic Tumors With 18F-Fluorothymidine and 18F- Fluorodeoxyglucose-Positron Emission Tomography.
Chest, February 1, 2006; 129(2): 393 - 401.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
D. L. Chen and F. Dehdashti
Advances in Positron Emission Tomographic Imaging of Lung Cancer
Proceedings of the ATS, December 1, 2005; 2(6): 541 - 544.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. R. Tseng, M. Dandekar, M. Subbarayan, Z. Cheng, J. M. Park, S. Louie, and S. S. Gambhir
Reproducibility of 3'-Deoxy-3'-18F-Fluorothymidine MicroPET Studies in Tumor Xenografts in Mice
J. Nucl. Med., November 1, 2005; 46(11): 1851 - 1857.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. M. Kenny, D. M. Vigushin, A. Al-Nahhas, S. Osman, S. K. Luthra, S. Shousha, R. C. Coombes, and E. O. Aboagye
Quantification of Cellular Proliferation in Tumor and Normal Tissues of Patients with Breast Cancer by [18F]Fluorothymidine-Positron Emission Tomography Imaging: Evaluation of Analytical Methods
Cancer Res., November 1, 2005; 65(21): 10104 - 10112.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
A-L Grosu, M Piert, and M Molls
Experience of PET for target localisation in radiation oncology
Br. J. Radiol., November 1, 2005; Supplement_28(1): 18 - 32.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Leyton, J. R. Latigo, M. Perumal, H. Dhaliwal, Q. He, and E. O. Aboagye
Early Detection of Tumor Response to Chemotherapy by 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography: The Effect of Cisplatin on a Fibrosarcoma Tumor Model In vivo
Cancer Res., May 15, 2005; 65(10): 4202 - 4210.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Waldherr, I. K. Mellinghoff, C. Tran, B. S. Halpern, N. Rozengurt, A. Safaei, W. A. Weber, D. Stout, N. Satyamurthy, J. Barrio, et al.
Monitoring Antiproliferative Responses to Kinase Inhibitor Therapy in Mice with 3'-Deoxy-3'-18F-Fluorothymidine PET
J. Nucl. Med., January 1, 2005; 46(1): 114 - 120.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. C.P. Cobben, P. H. Elsinga, H. J. Hoekstra, A. J.H. Suurmeijer, W. Vaalburg, B. Maas, P. L. Jager, and H. M.J. Groen
Is 18F-3'-Fluoro-3'-Deoxy-L-Thymidine Useful for the Staging and Restaging of Non-Small Cell Lung Cancer?
J. Nucl. Med., October 1, 2004; 45(10): 1677 - 1682.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Sugiyama, H. Sakahara, K. Sato, N. Harada, D. Fukumoto, T. Kakiuchi, T. Hirano, E. Kohno, and H. Tsukada
Evaluation of 3'-Deoxy-3'-18F-Fluorothymidine for Monitoring Tumor Response to Radiotherapy and Photodynamic Therapy in Mice
J. Nucl. Med., October 1, 2004; 45(10): 1754 - 1758.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. van Waarde, D. C.P. Cobben, A. J.H. Suurmeijer, B. Maas, W. Vaalburg, E. F.J. de Vries, P. L. Jager, H. J. Hoekstra, and P. H. Elsinga
Selectivity of 18F-FLT and 18F-FDG for Differentiating Tumor from Inflammation in a Rodent Model
J. Nucl. Med., April 1, 2004; 45(4): 695 - 700.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Barthel, E. Aboagye, and P. Price
Reply
Cancer Res., December 1, 2003; 63(23): 8560 - 8560.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
D. C.P. Cobben, P. H. Elsinga, A. van Waarde, and P. L. Jager
Correspondence re: H. Barthel et al., 3'-Deoxy-3'-[18F]fluorothymidine as a New Marker for Monitoring Tumor Response to Antiproliferative Therapy in Vivo with Positron Emission Tomography. Cancer Res., 63: 3791-3798, 2003.
Cancer Res., December 1, 2003; 63(23): 8558 - 8559.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.